Dr Reddy's Laboratories gets rights to sale Deflux in India

Oceana Therapeutics, a New Jersey-based pharmaceutical company, has entered into an exclusive multi-year agreement with Dr Reddy's Laboratories (DRL) giving it rights for the sale and distribution of its product, Deflux, in India, Oceana said in a statement.
      
Deflux is a proprietary speciality therapeutic used for the treatment of vesicoureteral reflux (VUR) - a malformation of the urinary bladder which affects children and can result in severe infections of the kidney and even irreversible kidney damage.
       
The Oceana Therapeutics said that net sales of Deflux worldwide were at $30 million. Oceana Therapeutics is an international company which focus on products serving the needs of the gastroenterology and urology specialities.
       
"Not a very big product in India. This product will help us increase our product depth and width in the segment. We are licensing more products like this just to increase the product offering to the doctor," Umang Vorha, chief financial officer of Dr Reddy’s told PTI.
       
In a statement, Gregory Stokes, Oceana's executive vice president, Business Development, said, "We are pleased to enter into this strategic association with Dr. Reddy’s, a global  pharmaceutical company with an exceptional knowledge of the India health care market and a solid operating infrastructure in that market, including some 80 urology sales representatives."
       
By leveraging the therapeutic value of Deflux with the strengths of Dr. Reddy's resources, we foresee a significant opportunity to serve a wider patient population in India with an important treatment for VUR, he said.